NEW YORK (GenomeWeb) – Vermillion continues to struggle to drive uptake of its OVA1 ovarian cancer test, but the company's fledgling in vitro diagnostic service business could provide an alternative revenue stream.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb or 360Dx Premium member?
Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.